SCAP and metabolic dysfunction-associated steatohepatitis: N-glycosylation of SCAP: Aberrant N-glycosylation of SREBP cleavage-activating protein (SCAP) exacerbates lipid accumulation and liver inflammation by enhancing histone H3 K27 acetylation mediated by acetyl-CoA synthetase 2 (ACSS2), leading to non-alcoholic steatohepatitis (NASH) (Li et al., 2024).